Refractory ascites (RA) is a complication of cirrhosis which is treated with large volume paracentesis (LVP) as the standard of care. Alfapump® system is a fully implantable pump system which reduces the need for LVP. The aim was to assess health-related quality of life (HRQL) in patients treated with alfapump® versus LVP.
The data were collected in a multicenter open-label randomized controlled trial (clinicaltrials.gov #NCT01528410). Subjects with cirrhosis Child–Pugh class B or C accompanied by RA were randomized to receive alfapump® or LVP. The SF-36v2 and CLDQ scores were compared between the two treatment arms at screening and monthly during treatment.
Of 60 subjects randomized, HRQL data were available for 58 (N = 27 received alfapump® and N = 31 received LVP only). At baseline, no differences were seen between the treatment arms (all p > 0.05): age 61.9 ± 8.4, 79.3% male, MELD scores 11.7 ± 3.3, 85.2% Child–Pugh class B, 70.7% had alcoholic cirrhosis. The mean number of LVP events/subject was lower in alfapump® than LVP (1.1 vs. 8.6, p < 0.001). The HRQL scores showed a moderate improvement from the baseline levels in subjects treated with alfapump® (p < 0.05 for abdominal and activity scores of CLDQ) but not with LVP (all one-sided p > 0.05) in the first 3 months. Multivariate analysis showed that treatment with alfapump® was independently associated with better HRQL at 3 months (total CLDQ score: beta = 0.67 ± 0.33, p = 0.05).
As compared to LVP, the use of alfapump® system is associated with both a reduction in the number of LVP events and improvement of health-related quality of life.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Transjugular intra-hepatic portosystemic shunt
Large volume paracentesis
Health-related quality of life
- alfapump® system:
Automated low-flow ascites pump system
Body mass index
Short form-36 version 2
Chronic Liver Disease Questionnaire
Physical component summary
Mental component summary
Chronic liver disease
Model for end-stage liver disease
Alcoholic liver disease
Moore, C. M., & Van Thiel, D. H. (2013). Cirrhotic ascites review: Pathophysiology, diagnosis and management. World Journal of Hepatology, 5(5), 251–263.
Planas, R., Montoliu, S., Ballesté, B., Rivera, M., Miquel, M., Masnou, H., et al. (2006). Natural history of patients hospitalized for management of cirrhotic ascites. Clinical Gastroenterology and Hepatology, 4(11), 1385–1394.
Runyon, B. A., & AASLD Practice Guidelines Committee. (2009). Management of adult patients with ascites due to cirrhosis: An update. Hepatology, 49(6), 2087–2107.
European Association for the Study of the Liver. (2010). EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology, 53(3):397–417.
Barsuk, J. H., Cohen, E. R., Feinglass, J., McGaghie, W. C., & Wayne, D. B. (2013). Clinical outcomes after bedside and interventional radiology paracentesis procedures. American Journal of Medicine, 126(4), 349–3 56.
Barsuk, J. H., Feinglass, J., Kozmic, S. E., Hohmann, S. F., Ganger, D., & Wayne, D. B. (2014). Specialties performing paracentesis procedures at university hospitals: Implications for training and certification. Journal of Hospital Medicine, 9(3), 162–168. https://doi.org/10.1002/jhm.2153.
Smith, M., & Durham, J. (2016). Evolving indications for TIPS. Techniques in Vascular and Interventional Radiology, 19(1), 36–41.
Copelan, A., Kapoor, B., & Sands, M. (2014). Transjugular intrahepatic portosystemic shunt: Indications, contraindications, and patient work-up. Seminars Interventional Radiology, 31(3), 235–242.
American College of Radiology, Society for Pediatric Radiology, and Society for Interventional Radiology. (2014). ACR-SIR-SPR practice parameter for the creation of a transjugular intrahepatic portosystemic shunt (TIPS), Amended 2014 (Resolution 39). Practice parameters and technical standards, pp. 1–22.
Teiusanu, A., Andrei, M., Arbanas, T., Nicolaie, T., & Diculescu, M. (2012). Nutritional status in cirrhotic patients. Maedica (Buchar), 7(4), 284–289.
Sorrentino, P., Castaldo, G., Tarantino, L., Bracigliano, A., Perrella, A., Perrella, O., et al. (2012). Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. Journal of Gastroenterology and Hepatology, 27(4), 813–822.
Younossi, Z. M., Boparai, N., McCormick, M., Price, L. L., & Guyatt, G. (2001). Assessment of utilities and health-related quality of life in patients with chronic liver disease. American Journal of Gastroenterology, 96(2), 579–583.
Solà, E., Watson, H., Graupera, I., Turón, F., Barreto, R., Rodríguez, E., et al. (2012). Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. Journal of Hepatology, 57(6), 1199 – 206.
Orr, J. G., Homer, T., Ternent, L., Newton, J., McNeil, C. J., Hudson, M., et al. (2014). Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology, 61(5), 1158–1165.
Bhanji, R. A., Carey, E. J., & Watt, K. D. (2017). Review article: Maximising quality of life while aspiring for quantity of life in end-stage liver disease. Alimentary Pharmacology and Therapy, 46(1), 16–25.
Jara, M., Bednarsch, J., Malinowski, M., Lüttgert, K., Orr, J., Puhl, G., Seehofer, D., Neuhaus, P., & Stockmann, M. (2014). Predictors of quality of life in patients evaluated for liver transplantation. Clinical Transplantation, 28(12), 1331–1338.
Bureau, C., Adebayo, D., Chalret de Rieu, M., Elkrief, L., Valla, D., Peck-Radosavljevic, M., et al. (2017). Alfapump® system versus large volume paracentesis for refractory ascites: A multicenter randomized controlled study. Journal of Hepatology, https://doi.org/10.1016/j.jhep.2017.06.010.
Moore, K. P., & Aithal, G. P. (2006). Guidelines on the management of ascites in cirrhosis. Gut, 55(Suppl 6), vi1–12.
Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.
Kharroubi, S. A., Brazier, J. E., Roberts, J., O’Hagan, A. (2007). Modelling SF-6D health state preference data using a nonparametric Bayesian method. Journal of Health Economics, 26(3), 597–612.
Younossi, Z. M., Stepanova, M., & Henry, L. (2016). Performance and validation of Chronic Liver Disease Questionnaire-hepatitis C version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health, 19(5), 544–551.
Ware, J. E., Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln, RI: Quality Metric Incorporated.
Fryback, D. G., Dunham, N. C., Palta, M., Hanmer, J., Buechner, J., Cherepanov, D., et al. (2007). US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Medical Care, 45(12), 1162–1170.
Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999). Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 45(2), 295–300.
Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 3(1), e000106.
Campbell, M. S., Brensinger, C. M., Sanyal, A. J., Gennings, C., Wong, F., Kowdley, K. V., et al. (2005). Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology, 42(3), 635–640.
Afendy, A., Kallman, J. B., Stepanova, M., Younoszai, Z., Aquino, R. D., Bianchi, G., Marchesini, G., & Younossi, Z. M. (2009). Predictors of health-related quality of life in patients with chronic liver disease. Alimentary Pharmacology Therapy, 30(5), 469–476.
Adebayo, D., Bureau, C., Valla, D., Peck-Radosavljevic, M., McCune, A., Vargas, V., et al. (2015). Alfapump® system versus large volume paracentesis in the treatment of refractory ascites. A multicenter randomised controlled study. Journalof Hepatology, 62(Suppl 2), S849–S850.
Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Liappas, I. (2007). Should impaired liver function be held responsible for cognitive impairment and poor health-related quality of life in alcoholic cirrhosis? Hepatology, 46(3):950; author reply 951.
Imtiaz, S., Loheswaran, G., Le Foll, B., & Rehm, J. (2017). Longitudinal alcohol consumption patterns and health-related quality of life: Results from the National Epidemiologic Survey on alcohol and related conditions. Drug and Alcohol Review, https://doi.org/10.1111/dar.12503.
Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41(4), 790–800.
Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality Life Outcomes, 1(1), 4.
Loria, A., Escheik, C., Gerber, N. L., & Younossi, Z. M. (2013). Quality of life in cirrhosis. Current Gastroenterology Reports, 15(1), 301. https://doi.org/10.1007/s11894-012-0301-5. Review. PubMed PMID: 23250701.
This study was funded by Sequana Medical.
Conflict of interest
ZMY is a consultant or advisory board of Abbvie, Intercept, Gilead Sciences, Salix, GSK, BMS, Allergan, Sanofi, and Novo Nordisk. RJ has research collaborations with Ocera, and Yaqrit, consults for Ocera and Yaqrit, and has received speaking and consultation fees from Sequana. RJ is the founder of Yaqrit Limited, which is developing UCL inventions for treatment of patients with cirrhosis. LE had received funding from Sequana for reporting of the data into the CRF for this study. DV received an honorarium from Sequana Medical for this clinical study, is a consultant on the Liver Safety Committee of Laboratoires Servier, and has provided teaching services for Gilead Sciences. PA is a member of the Sequana Medical AG Advisory Board, the LAT Pharma LLC Advisory Board, and the Gilead Advisory Board in Italy. Other co-authors have indicated that they have no potential conflicts of interest to disclose.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Stepanova, M., Nader, F., Bureau, C. et al. Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Qual Life Res 27, 1513–1520 (2018). https://doi.org/10.1007/s11136-018-1813-8
- Alcoholic liver disease